ACBD4

Studies have shown that ACBD4 expression is altered in metabolic diseases such as obesity and diabetes. ACBD4 knockout mice exhibit reduced body weight, improved glucose tolerance, and reduced hepatic steatosis, suggesting that ACBD4 may be a potential target for the treatment of metabolic diseases.

It is generally stable when stored at -20°C or -80°C for up to six months to two years, respectively. However, the protein may be sensitive to freeze-thaw cycles, and repeated freeze-thaw cycles should be avoided. It is also recommended to aliquot the protein upon arrival to minimize the number of freeze-thaw cycles.

Yes, it can be used in a variety of functional assays, such as enzyme assays, binding assays, and activity assays, to study its biochemical and biophysical properties.

It may vary depending on the application and the specific experimental conditions. Typically, a concentration of 0.1-1 mg/mL is sufficient for most assays, but this may need to be optimized based on the experimental setup. It is recommended to use a range of concentrations to determine the optimal concentration for a specific experiment.

It varies depending on the specific application. It is important to verify the appropriate concentration for each specific application in order to ensure optimal results.

The endotoxin concentration is typically below 1.0 eu/μg of protein, as determined by a Limulus Amebocyte Lysate (LAL) assay. In addition, you can choose the concentration you need when submitting the inquiry form.

You can describe your experimental needs in detail to our scientists, such as WB, IF, IP, IHC, and they will provide professional solutions.

It should be stored at -20°C or -80°C in a non-frost free freezer. It is important to avoid repeated freeze-thaw cycles in order to prevent degradation of the protein. It is recommended that the protein be aliquoted into smaller portions to avoid contamination from repeated use.

ACBD4 protein contains an N-terminal acyl-CoA binding domain that binds to long-chain acyl-CoA esters and a C-terminal domain that interacts with the Golgi membrane. It also contains a hydrophobic loop that plays a crucial role in the binding of ACBD4 to the Golgi membrane.

Several signaling pathways, including the AMP-activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) pathways, have been shown to regulate ACBD4 expression.